2024
Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Shah R, Wilkins S, Safranek C, Shah H, Brophy C, Mehra S. Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head & Neck Surgery 2024, 150 PMID: 39418066, PMCID: PMC11581730, DOI: 10.1001/jamaoto.2024.3237.Peer-Reviewed Original ResearchHPV-positive oropharyngeal squamous cell carcinomaOropharyngeal squamous cell carcinomaSquamous cell carcinomaDistant metastasisDisease recurrenceCell carcinomaRecurrence detectionHuman papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomaCohort studyMethod of recurrence detectionSurveillance strategiesSurveillance imaging strategiesLocation of recurrencePatterns of recurrenceFollow-up timeElectronic medical record reviewOptimal surveillance strategyPercentage of patientsRetrospective cohort studyIncidence of DMTertiary care hospitalDiagnosis to deathMedical record reviewRecurrence cohortRegional recurrence
2020
Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer
Jacobs D, Torabi SJ, Park HS, Rahmati R, Young MR, Mehra S, Judson BL. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. Otolaryngology 2020, 164: 1240-1248. PMID: 33198564, DOI: 10.1177/0194599820969613.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseHPV-negative oropharyngeal cancersChemoradiation therapyOverall survivalCancer DatabaseOropharyngeal cancerHPV-negative oropharyngeal squamous cell carcinomaLarge national cancer databaseNeck cancer-specific survivalOropharyngeal squamous cell carcinomaCox proportional hazards regressionKaplan-Meier survival analysisCancer-specific survivalImproved overall survivalMultivariable Cox regressionRetrospective cohort studyAdjuvant chemoradiation therapyUse of surgeryEnd Results ProgramProportional hazards regressionSquamous cell carcinomaSEER cohortAdjuvant therapyCohort studySEER database
2015
Postmarket Modifications of High‐Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration
Rathi VK, Ross JS, Samuel AM, Mehra S. Postmarket Modifications of High‐Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration. Otolaryngology 2015, 153: 400-408. PMID: 26044785, DOI: 10.1177/0194599815587508.Peer-Reviewed Original ResearchConceptsClinical dataUS FoodDrug AdministrationPMA pathwayRetrospective cohort studyAdditional clinical dataPremarket approval pathwaySignificant clinical implicationsCohort studyHigh-risk medical devicesMedian numberClinical implicationsMarketing clearanceLife spanAdministrationSubstantial numberPMA applicationApproval pathwaySupplementsFDATherapeutic devicesPathway
2011
Outcomes of Temporal Bone Resection for Locally Advanced Parotid Cancer
Mehra S, Morris L, Shah J, Bilsky M, Selesnick S, Kraus D. Outcomes of Temporal Bone Resection for Locally Advanced Parotid Cancer. Journal Of Neurological Surgery Part B Skull Base 2011, 21: 389-396. PMID: 22547966, PMCID: PMC3312127, DOI: 10.1055/s-0031-1287682.Peer-Reviewed Original ResearchLateral temporal bone resectionRecurrence-free survivalAdvanced parotid cancerTemporal bone resectionParotid cancerLocoregional controlMost patientsDisease recurrenceBone resectionDisease-specific survival ratesActuarial locoregional controlBetter locoregional controlExtended radical parotidectomyRetrospective cohort studyAcceptable complication rateKaplan-Meier methodSurgical margin statusCox multivariate regressionGross total resectionLong-term survivalCohort studyComplication rateIndependent predictorsLocal recurrenceMargin status